InterMune Halts Phase III Actimmune Lung Disease Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will focus on pirfenidone for idiopathic pulmonary fibrosis after Actimmune failed to show a statistically significant treatment effect over placebo.
You may also be interested in...
InterMune’s Idiopathic Pulmonary Fibrosis Push Continues As Actimmune Sales Slump
Data support gambling on experimental pirfenidone against “incredibly complex” disease, chief scientific officer tells “The Pink Sheet” DAILY.
InterMune’s Idiopathic Pulmonary Fibrosis Push Continues As Actimmune Sales Slump
Data support gambling on experimental pirfenidone against “incredibly complex” disease, chief scientific officer tells “The Pink Sheet” DAILY.
Actimmune Trial INSPIREs InterMune To Enlarge Pirfenidone Studies, Make Cuts
Biotech announces plans to reduce operating expenses and cut 50 percent of its staff.